---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-005671"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2021-08-09T23:59:59+00:00"
generated_at: "2026-06-29T19:40:30.806910+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioCryst CBO Megan Sniecinski departs Aug 9; severance of $658,634 plus accelerated option vesting

## Summary
- Megan Sniecinski, Chief Business Officer, separates effective August 9, 2021; previously disclosed on Aug 3.
- Severance payment of $658,634.04 paid in equal installments over one year.
- 100% of unvested options from July 2019 & Dec 2019, and 75% from Dec 2020, accelerate to vested.
- COBRA premiums paid for up to 18 months; 180-day post-separation option exercise window.
- Agreement includes one-year non-compete in therapeutic areas (HAE, FOP, PNH, etc.) and non-solicitation.

## SEC filing metadata
- accession: 0001171843-21-005671
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2021-08-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184321005671/0001171843-21-005671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184321005671/f8k_080921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-005671
- JSON: https://secwatch.observer/filing/0001171843-21-005671.json
- Plain text: https://secwatch.observer/filing/0001171843-21-005671.txt

## Key facts
- Executive change
  Megan Sniecinski departed as Chief Business Officer at BIOCRYST PHARMACEUTICALS INC.
  - Action: separated
  - Role: Chief Business Officer
  source text: Megan Sniecinski, Chief Business Officer of the Company, would separate from employment with the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184321005671/0001171843-21-005671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.